In contrast, another paper showed that CD133+ cells express more cancer stem-cell markers and exhibit an enhanced proliferation rate [21,22], resistance to chemotherapeutics [22,23], and enhanced tumorigenicity in immunodeficient mice in vivo [22,23]. The gene discussed is PROM1; the disease is cancer.